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The diagnosis of pheochromocytoma is based on the
quantitation of O-methylated metabolites of catechol-
amines (1, 2). Several studies have reported high sen-
sitivity of free metanephrines in plasma for assessing
the presence of tumour (1). Measurement of plasma
total metanephrines (plasma freeqplasma sulpho-
conjugated metanephrines) has also been proposed
as a diagnostically sensitive assay (3). Therefore, an
increasing number of laboratories have developed
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assays for free and total metanephrines using differ-
ent analytical procedures including immunoassays (4,
5), high-performance liquid chromatography (HPLC)
coupled to amperometric or coulometric detection (6)
and liquid chromatography-tandem mass spectrom-
etry (LC-MS) methods (7). Each laboratory is sup-
posed to establish its own reference values and to
perform quality control measurements (QCs) with
each set of analyses. The internal QC samples usually
are prepared by each laboratory and should include
plasma samples spiked with known concentrations of
both metanephrine (MN) and normetanephrine
(NMN). Participation in an external quality assess-
ment scheme (EQAS) allows direct comparisons
between all laboratories that measure free and total
metanephrines. In this context, the variability of the
upper reference limit for free metanephrines reported
in the literature is relatively large. For NMN the range
varies from 0.6 to 1.4 nmol/L, and for MN it varies
from 0.3 to 0.85 nmol/L (1, 2, 8). However, the upper
reference limits for total metanephrines are better
defined (3, 9, 10). The analytical procedure for the
quantitation of metanephrines in plasma is not the
only reason for this variability. The characteristics of
the control population may also differ between differ-
ent studies. The absence of a universal calibrator that
could be used by all laboratories performing such
measurements encouraged us to establish an EQA
program for plasma free and total metanephrines. A
similar program already exists for metanephrines and
catecholamines in urine. The purpose of this letter is
to present the results of a pilot study aimed at imple-
menting a proficiency survey for all laboratories
measuring plasma free and/or total metanephrines.
We selected 10 centres that routinely measure free
and/or total plasma metanephrines for diagnosis of
pheochromocytoma. Three analytical methods were
used. Immunoassays (1 participant), HPLC with elec-
trochemical detection (ECD) (8 participants) including
amperometry, coulometry, coularray and LC-MS (1
participant). All but one laboratory, which used an RIA
commercial kit method, used in-house methods. Cal-
ibrators and internal quality control samples were
manufactured using spiked serum pools with stan-
dard dilutions of Sigma D, L MN and NMN. The sur-
vey provided one result for free metanephrines in
plasma by radioimmunoassay (RIA), one by LC-MS
and five by LC-ECD while sulpho-conjugated meta-
nephrines gave one result by LC-MS and four by LC-
ECD. Two types of matrices were compared. Although
heparinised plasma is normally used by the majority
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of the laboratories, this matrix was not used since it
forms aggregates during lyophilisation of the samples
and may affect analysis. Therefore, one laboratory
involved in this study (HPLC with coularray detection,
Eric Grouzmann) compared heparinised and citrated
plasma samples collected from three different sub-
jects; the concentrations of free metanephrines found
in the two matrices were similar. In addition, the chro-
matographic profiles were clean in both sample types
(data not shown). Therefore, we decided to use serum
and citrated plasma as an alternative matrix to hep-
arin. Serum (samples 1 and 2) and citrate plasma
(samples 3 and 4) were prepared by RECIPE (RECIPE
CHEMICALS & INSTRUMENTS GmbH, Munich, Ger-
many), a company that produces quality control
materials as lyophylisates to be reconstituted in
water. The citrate-plasma (CPD-plasma) that we used
for preparing the EQA-samples was prepared from an
aliquot of a pool from 36 individuals (pool volume in
total: ;10 L). Serum was used from a pool prepared
from more than 100 individuals. The samples con-
tained normal, but unknown concentrations of NMN
and MN. A second set of samples (samples 2 and 4)
were spiked with exogenous NMN (956 pmol/L) and
MN (456 pmol/L) to mimic concentrations observed in
plasma of a patient with pheochromocytoma. Since
sulpho-conjugated metanephrines standards were
not available for spiking experiments, we were unable
to assess their recovery. Methods used for hydrolys-
ing sulpho-conjugated metanephrines included incu-
bation of the sample with sulphatase or, alternatively,
perchloric acid precipitation of proteins from serum,
followed by boiling.
For the immunological method, the recovery was
only 50% of the added amount of NMN and MN. This
is because the antibodies used in the RIA are stereo-
selective and only measure the physiological form of
metanephrines, while the exogenous spiking material
contains both the D and L forms of NMN and MN.
Therefore, results obtained for samples spiked with
NMN and MN, using immunoassay methods, were
corrected to compensate for D isomers that were not
measured as follows: corrected concentration of
spiked sampless2=concentration of spiked sam-
ple–concentration of unspiked sample. The lyophili-
sates were shipped to PROBIOQUAL, a non-profit
French centre that organises external quality surveys
for laboratories. The data were directly sent to PRO-
BIOQUAL who provided the survey results to the
study coordinator (Eric Grouzmann). The number of
participants in this pilot study was too low to allow
for extensive statistical evaluation of results. There-
fore, data were compared on the basis of means and
recoveries of spiked metanephrines, and we only
compared the overall recoveries of metanephrines
added in plasma and serum by mean of a two-way
ANOVA. Inter- and intra-method coefficients of vari-
ation observed between all the results were also
reported. The dispersion of concentrations reported
for free NMN and MN was relatively small between
laboratories. Percent CVs ranged from 10% to 34%.
The results for MN from laboratory 3 were excluded
since they were very high (probably HPLC interfer-
ence). Percent CVs were similar for serum and plasma
free NMN and MN (Table 1). Mean concentrations of
free NMN from citrate plasma were different,
although in the same range, compared to those meas-
ured in serum because the serum and citrate pools
were not obtained from the same subjects. MN con-
centrations were relatively similar between all tech-
niques and matrices. A single group sent results
obtained with a LC-MS method that was presumed to
be free of any interferences linked to chromatograph-
ic artefacts or immunoassay matrix effects. Results
for free MN measured with LC-MS methods were very
similar to those observed with HPLC-ECD and immu-
nological methods. Free NMN concentrations were
significantly lower with immunological methods, even
after correction of spiked results for the D-isomer. The
overall recoveries on samples spiked with metane-
phrines were similar for free NMN and MN, and
between the two matrices used for the study (ps0.58
for NMN and ps0.14 for MN). These results indicate
that serum may be substituted for citrate plasma.
HPLC-ECD methods allowed better recovery com-
pared with immunological method, while LC-MS
method provided the highest recovery of spiked free
metanephrines (Table 2).
The dispersion of concentrations of total NMN and
MN observed between the five laboratories was high-
er than those obtained with free metanephrines
(33%–44% vs. 10%–34%) Table 1.
Plasma free metanephrines represent one of the
best biochemical markers for biochemical assessment
of a pheochromocytoma. Validation for this assay is
difficult because the circulating concentrations of free
metanephrines are -1 nmol/L.
Therefore, it is crucial to implement procedures that
will help different laboratories measuring free meta-
nephrines in plasma in order to control the different
analytical steps of their assay. Plasma total metane-
phrines have not been investigated as thoroughly,
although they have been described as being poten-
tially sensitive markers for pheochromocytomas (3).
External quality control is essential to establish in a
‘‘peer-review’’ manner that all results provided by the
laboratories involved are relatively similar and accu-
rate. The variability obtained in this preliminary study
with plasma free metanephrines was double the var-
iability usually found by PROBIOQUAL for urinary
metanephrines, although with a higher number of
participants (11). Improvement of the CVs would be
necessary to allow better comparisons of the concen-
trations between the centres.
It appears that free NMN, but not free MN concen-
trations, were systematically lower with immuno-
assay independent of the matrix. This fact should be
taken into account when patients are followed by dif-
ferent centres. Correction of recovery based on the
addition of the racemate of metanephrines into sam-
ples should be interpreted with caution, since matrix
effects were not taken into account during this
calculation. The overall recoveries were similar for
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Table 2 Recoveries of plasma free metanephrines expressed in percent of added metanephrines in sera (sample 2) and
plasma (sample 4) spiked with 956 pmol/L of normetanephrine and 456 pmol/L of metanephrine.
Laboratory no. Methods Samples
2 4
NMN MN NMN MN
1 RIA 63 57 62 78
2 HPLC ECD 110 93 112 84
3 HPLC ECD 47 91
4 HPLC ECD 84 76 78 92
5 HPLC ECD 111 75 109 79
6 HPLC ECD 67 64 66 75
7 HPLC-LC/MS 98 88 91 90
All results Mean 83 76 87 83
SD 25 14 20 7
CV% 30 18 22 8
Immunological method 63 57 62 78
HPLC methods Mean 84 77 91 83
SD 28 12 20 7
CV% 33 16 22 6
LC-MS method 98 88 91 90
NMN, normetanephrine; MN, metanephrine; RIA, radioimmunoassay; ECD, electrochemical detection; LC-MS, liquid chro-
matography-tandem mass.
serum and citrate plasma, but were in favour of HPLC
methods compared to immunoassays. This indicates
that the lyophilisation process did not cause a signif-
icant loss of metanephrines.
Surprisingly, the variability observed with total
metanephrines was higher than expected since the
concentrations of sulpho-conjugated metanephrines
are about 10-fold higher than free metanephrines.
These discrepancies may depend on the protocol
used for sample preparation. Indeed, differences in
efficiency may occur when the procedure used to
deconjugate metanephrines consists of perchloric
acid hydrolysis followed by heating or treatment with
sulphatase.
The variability encountered between assays is most
often due to calibrators, independent of the analytical
methods used. Therefore, a universal matrix calibra-
tor would definitely help improve the accuracy of MN
assays. One of the limitations of our pilot study is the
fact that the number of centres involved in the eval-
uation is relatively low. This makes it difficult to draw
definitive conclusions about the variability observed
between the groups. However, the Royal College of
Pathologists of Australasia (RCPA QAP) has a special
program available for plasma free metanephrines in
2009 that may confirm our preliminary results based
on a single survey. Another limitation is the fact that
the immunological method and the LC-MS method
are represented by only one laboratory in this study;
these results should be considered with caution.
In conclusion, we have established the conditions
necessary to improve harmonisation of the results
obtained for plasma free and total metanephrines.
Further long-term proficiency tests with more parti-
cipants should be performed to better evaluate the
accuracy observed between laboratories.
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